Monopar Therapeutics (Monopar Therapeutics) Cash per Share : $0.50 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Monopar Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 was $0.50.

Monopar Therapeutics Cash per Share Historical Data

The historical data trend for Monopar Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Cash per Share Chart

Monopar Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

1.25

1.46

1.61

1.01

0.49

Monopar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															0.88	0.73	0.60	0.49	0.50

Monopar Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Monopar Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	7.266	/	14.90
	=	0.49

Monopar Therapeutics's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	8.793	/	17.48
	=	0.50

Monopar Therapeutics (NAS:MNPR) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Monopar Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Monopar Therapeutics (Monopar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

1IY:Germany

Address

1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website

https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Executives

Michael J Brown	director	C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner	director	ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson	director	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto	officer: Chief Financial Officer	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson	director, officer: Chief Executive Officer	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Andrew Cittadine	officer: Chief Operating Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Patrice Rioux	other: Acting Chief Medical Officer	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr	director	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa	officer: Chief Medical Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc	10 percent owner	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson	officer: SVP, Clinical Development	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc	10 percent owner	C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc	10 percent owner	1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091